The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Description: Project Narrative: A clinical trial is proposed to evaluate the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently or in combination, to improve the beneficial effect of bone marrow derived stem cells (derived from bone marrow aspirate concentrate) for improving outcomes in patients with knee osteoarthritis. These proposed clinical trials will build upon a currently active clinical trial on orthobiologics at TSC/SPRI for OA treatment at SPRI utilizing the same patient population and outcomes assessments to effectively provide a 6-arm, comprehensive assessment of biological therapies for improving treatment of osteoarthritis.
Funding type: cooperative_agreement
Funder scheme: UG3
Start date: 2020-08-01
End date: 2021-07-31
Investigator: JOHNNY HUARD
Institution: STEADMAN PHILIPPON RESEARCH INSTITUTE
Funded outputs count: 5
Funder award ID: UG3AR077748
OpenAlex ID: G7263685928